| |
Newsroom /
Health and Fitness
/
Healthcare
/
Acute Spinal Cord Injury (ASCI) Therapeutics – Pipeline Assessment and Market Forecasts to 2017
Acute Spinal Cord Injury (ASCI) Therapeutics – Pipeline Assessment and Market Forecasts to 2017
Acute SCI Therapeutics Market is Forecast to Show Slow Growth to 2017
Hyderabad,
AP,
India
(prbd.net)
30/05/2011
GlobalData estimated the acute spinal cord injury (ASCI) therapeutics market to be worth $44.78m in 010 and forecasts it to grow at a CAGR of 6.3% to reach $68.76m in 2017. This predicted growth is rimarily attributed to the increasing incidence of SCIs and a larger treatment seeking population. There is nly one molecule, Lyrica (pregabalin) in Phase III of the pipeline, which targets the pain associated with CIs. This molecule only offers symptomatic relief and is not likely to have a significant impact on the SCI therapeutics market. The lack of specific approved neuroprotective and neuroregenerative therapies s a barrier for the acute SCI therapeutics market.
GlobalData’s analysis reveals that the current competition in the ASCI therapeutics market is weak. The arket lacks a therapy specifically approved by the FDA (Food and Drug Administration) or the EMEA European Medicines Agency) for the treatment of SCIs. Medrol (methylprednisolone), which helps to educe swelling in the spinal cord, is widely prescribed as an off-label drug. However, it is unable to ompletely serve the market’s unmet needs. The absence of effective treatment options clearly signifies hat the current competition in the ASCI market is weak.
For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages.aspx?ID=Acute-Respiratory-Distress-Syndrome-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017&Title=Pharmaceuticals_and_Healthcare&ReportType=Industry_Report
The pipeline consists of 19 products in different stages of development. Neuropathic pain is a common ymptom among patients. Pregabalin, which targets neuropathic pain, is currently in Phase III. There are 2 drugs in the preclinical and discovery stages of development. However, the later stages of the evelopmental pipeline contain only three molecules. Phase III contains pregabalin, which is a voltage ated calcium channel modulator. Phase II includes, Umbilical Cord Blood Mononuclear Cell Transplants,
which are aimed at improving functional recovery in patients, and ProCord, an autologous activated acrophage therapy, aimed at facilitating neuroprotecion and wound healing. All of the drugs in the ipeline are first-in-class drugs, with 84% of the pipeline dominated by molecules exhibiting europrotective and neuronal regeneration characteristics. Out of the 84%, the molecules in the discovery nd the preclinical stages contribute around 88%. This suggests that the pipeline intensity in the clinical
Phases is weak and that research and development (R&D) is mainly focused in the discovery and reclinical stages. These products are expected to meet some unmet needs and will provide physicians ith better options for treating SCIs. A key factor is that none of these first-in-class drugs are likely to mpact the SCI therapeutics market before 2017.
GlobalData, the industry analysis specialist, has released its new report, “Acute Spinal Cord Injury (ASCI) Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global SCI market. The report identifies the key trends shaping nd driving the global ASCI market. The report also provides insights on the prevalent competitive andscape and the emerging players expected to significantly alter the market positioning of the current arket leaders. Most importantly, the report provides valuable insights on the pipeline products within the lobal ASCI sector. This report is built using data and information sourced from proprietary databases, rimary and secondary research and in-house analysis by GlobalData’s team of industry experts.
For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Acute-Respiratory-Distress-Syndrome-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017&Title=Pharmaceuticals_and_Healthcare&ReportType=Industry_Report
Visit our report store: http://www.globaldata.com
For more details contact:
pressreleases@globaldata.com
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782
About
GlobalData is a global market intelligence services company providing information research and analysis products and services.
|